MISSOURI VALLEY CANCER CONSORTIUM

拟议的密苏里谷癌症联盟(MVCC)将是一个多 以奥马哈为基础的基于社区的癌症研究工作 林肯，内布拉斯加州。集水区包括爱荷华州西部和东部- 内布拉斯加州中部。1990年的人口约为120万。 奥马哈分支机构被誉为最大的收款方之一 中北部癌症治疗组的患者。--四个主要 MVCC的组成部分将是：Bergan Mercy医疗中心，兰登& 布洛克，P.C.，林肯癌症中心和克雷顿癌症中心。 这些机构已经与朝鲜建立了研究计划 中央癌症治疗小组(NCCTG)自1983年以来。无数调查人员 (33)参与并负责2990多名新增癌症患者 每年一次。在过去的10年里，这些调查人员已经进入了1628 仅使用NCCTG方案的患者最近平均为285名患者 每年一次。1992年，这些调查人员分别输入了191名和94名患者 NCI批准的癌症治疗试验和对照试验。这个 建议的MVCC首席调查员和副首席调查员是 目前指导开展乳腺癌预防试验(97 )和前列腺癌预防试验(启动 10/93)为内布拉斯加州。目前的研究基地隶属于 NCCTG、ECOG和NSABP将继续并在未来支持 作为NCI资助的CCOP，这种高水平的应计利润。

The proposed Missouri Valley Cancer Consortium (MVCC) will be a multi- component community-based cancer research effort based in Omaha and Lincoln, Nebraska. The catchment area includes western Iowa and east- central Nebraska. The 1990 population was about 1.2 million. The Omaha affiliate has been commended as one of the largest accruers of patients in the North Central Cancer Treatment Group. The--four main components of the MVCC would be: Bergan Mercy Medical Center, Langdon & Block, P.C., Lincoln Cancer Center, and the Creighton Cancer Center. These institutions have had an established research program with the North Central Cancer Treatment Group (NCCTG) since 1983. Numerous investigators (33) participate and are responsible for over 2,990 new cancer patients annually. Over the past 10 years, these investigators have entered 1,628 patients on NCCTG protocols alone with recent average of 285 patients annually. In 1992, these investigators entered 191 and 94 patients on NCI-approved cancer treatment and control trials, respectively. The proposed principal and associate principal investigators of the MVCC are currently directing the conduct of the Breast Cancer Prevention Trial (97 accrued to date) and the Prostate Cancer Prevention Trial (initiation 10/93) for the state of Nebraska. Current research base affiliations with NCCTG, ECOG, and NSABP would continue and enable the future support of this high level of accrual as a NCI-funded CCOP.